Dataset Information

A machine learning and network framework to discover new indications for small molecules.

ABSTRACT: Drug repurposing, identifying novel indications for drugs, bypasses common drug development pitfalls to ultimately deliver therapies to patients faster. However, most repurposing discoveries have been led by anecdotal observations (e.g. Viagra) or experimental-based repurposing screens, which are costly, time-consuming, and imprecise. Recently, more systematic computational approaches have been proposed, however these rely on utilizing the information from the diseases a drug is already approved to treat. This inherently limits the algorithms, making them unusable for investigational molecules. Here, we present a computational approach to drug repurposing, CATNIP, that requires only biological and chemical information of a molecule. CATNIP is trained with 2,576 diverse small molecules and uses 16 different drug similarity features, such as structural, target, or pathway based similarity. This model obtains significant predictive power (AUC = 0.841). Using our model, we created a repurposing network to identify broad scale repurposing opportunities between drug types. By exploiting this network, we identified literature-supported repurposing candidates, such as the use of systemic hormonal preparations for the treatment of respiratory illnesses. Furthermore, we demonstrated that we can use our approach to identify novel uses for defined drug classes. We found that adrenergic uptake inhibitors, specifically amitriptyline and trimipramine, could be potential therapies for Parkinson's disease. Additionally, using CATNIP, we predicted the kinase inhibitor, vandetanib, as a possible treatment for Type 2 Diabetes. Overall, this systematic approach to drug repurposing lays the groundwork to streamline future drug development efforts.

SUBMITTER: Gilvary C

PROVIDER: S-EPMC7437923 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A machine learning and network framework to discover new indications for small molecules.

Gilvary Coryandar C Elkhader Jamal J Madhukar Neel N Henchcliffe Claire C Goncalves Marcus D MD Elemento Olivier O

PLoS computational biology 20200807 8

Drug repurposing, identifying novel indications for drugs, bypasses common drug development pitfalls to ultimately deliver therapies to patients faster. However, most repurposing discoveries have been led by anecdotal observations (e.g. Viagra) or experimental-based repurposing screens, which are costly, time-consuming, and imprecise. Recently, more systematic computational approaches have been proposed, however these rely on utilizing the information from the diseases a drug is already approved ...[more]

PMID: 32764756

Similar Datasets

Project description:Light-absorbing organic molecules are useful components in photocatalysts, but it is difficult to formulate reliable structure-property design rules. More than 100 million unique chemical compounds are documented in the PubChem database, and a significant sub-set of these are π-conjugated, light-absorbing molecules that might in principle act as photocatalysts. Nature has used natural selection to evolve photosynthetic assemblies; by contrast, our ability to navigate the enormous potential search space of organic photocatalysts in the laboratory is limited. Here, we integrate experiment, computation, and machine learning to address this challenge. A library of 572 aromatic organic molecules was assembled with diverse compositions and structures, selected on the basis of availability in our laboratory, rather than more sophisticated criteria. This training library was then assessed experimentally for sacrificial photocatalytic hydrogen evolution using a high-throughput, automated method. Quantum chemical calculations and machine learning were used to visualise, interpret, and ultimately to predict the photocatalytic activities of these molecules, covering a much broader chemical space than for previous polymer photocatalyst libraries. By applying unsupervised learning to the molecular structures, we identified structural features that were common in molecules with high catalytic activity. Further analysis using calculated molecular descriptors within a suite of supervised classification algorithms revealed that light absorption, exciton electron affinity, electron affinity, exciton binding energy, and singlet-triplet energy gap had correlations with the photocatalytic performance. These trained predictive models can be used in future studies as filters to deprioritise or discard would-be low-activity candidate molecules from experiments, and to prioritize more favourable candidates. As a demonstration, we used virtual in silico experiments to show that it was possible to halve the experimental cost of finding 50% of the most active photocatalysts by using the machine learning model as an experimental advisor. We further showed that the ML advisor trained on the 572-molecule library could be used to make predictions for an unseen set of 96 molecules, achieving equivalent predictive accuracies to those in the initial training set. This marks a step toward the machine-learning assisted discovery of molecular organic photocatalysts and the approach might also be applied to problems beyond photocatalytic hydrogen evolution, such as CO2 reduction and photoredox chemistry.

Project description:Bcl-2 family anti-apoptotic proteins are overexpressed in several hematological and solid tumors, and contribute to tumor formation, progression, and resistance to therapy. They represent a promising therapeutic avenue to explore for cancer treatment. Venetoclax, a Bcl-2 inhibitor is currently used for hematological malignancies or is undergoing clinical trials for either hematological or solid tumors. Despite these progresses, ongoing efforts are focusing on the identification and development of new molecules targeting Bcl-2 protein and/or other family members. Methods: Machine learning guided virtual screening followed by surface plasmon resonance, molecular docking and pharmacokinetic analyses were performed to identify new inhibitors of anti-apoptotic members of Bcl-2 family and their pharmacokinetic profile. The sensitivity of cancer cells from different origin to the identified compounds was evaluated both in in vitro (cell survival, apoptosis, autophagy) and in vivo (tumor growth in nude mice) preclinical models. Results: IS20 and IS21 were identified as potential new lead compounds able to bind Bcl-2, Bcl-xL and Mcl-1 recombinant proteins. Molecular docking investigation indicated IS20 and IS21 could bind into the Beclin-1 BH3 binding site of wild type Bcl-2, Bcl-xL and Mcl-1 proteins. In particular, although the IS21 docked conformation did not show a unique binding mode, it clearly showed its ability in flexibly adapting to either BH3 binding sites. Moreover, both IS20 and IS21 reduced cell viability, clonogenic ability and tumor sphere formation, and induced apoptosis in leukemic, melanoma and lung cancer cells. Autophagosome formation and maturation assays demonstrated induction of autophagic flux after treatment with IS20 or IS21. Experiments with z-VAD-fmk, a pan-caspase inhibitor, and chloroquine, a late-stage autophagy inhibitor, demonstrated the ability of the two compounds to promote apoptosis by autophagy. IS21 also reduced in vivo tumor growth of both human leukemia and melanoma models. Conclusion: Virtual screening coupled with in vitro and in vivo experimental data led to the identification of two new promising inhibitors of anti-apoptotic proteins with good efficacy in the binding to recombinant Bcl-2, Bcl-xL and Mcl-1 proteins, and against different tumor histotypes.

Dataset Information

A machine learning and network framework to discover new indications for small molecules.

Publications

A machine learning and network framework to discover new indications for small molecules.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets